Dewey Library - LC1085.B85 2014

Francis, Anthony

Roldan, Leslie, author

Krantz, Steven G. (Steven George), 1951- author

Agency probing alleged irregular re-allotment of Panchkula plot to firm in 2005

Asks officers to fact-check and refer to reliable sites to verify news reports

Many fund houses don't yet offer the pause facility but are scrambling to put one in place for investors

The rise in premiums could be in the range of 5-25 per cent, depending on the features that each insurance company adds on its products

When Kriti and Govinda set the stage on fire

Golf industry sets three-stage to reopening US courses

Tiger Woods, Phil Mickelson, Peyton Manning and Tom Brady showdown set for May 24

The government's decision of upholding power purchase agreements as well as the opening up of railways, city gas distribution, and electricity supply to the private sector, are welcome steps

She further said that many people have been speculating that the fiscal deficit would cross 4%

Interview with Richard Mayeux, MD, MSc, author of Variants in the ATP-Binding Cassette Transporter (ABCA7), Apolipoprotein E ε4, and the Risk of Late-Onset Alzheimer Disease in African Americans

Between 8% and 10% of the population will have a seizure at one point in life. It's important to distinguish seizures from other entities that can look like them and, once a diagnosis of a seizure is established, know how to treat them. In this JAMA Clinical Review podcast, we discuss seizures and epilepsy with Jay Gavvala, MD, author of New-Onset Seizure in Adults and Adolescents: A Review.

Article discussed in this episode:

New-Onset Seizure in Adults and Adolescents: A Review

Workplace violence–related injuries occur disproportionately in health care settings. In this podcast, we discuss how individual clinicians should manage violent patients who might attack them. Article discussed in this episode: Ensuring Staff Safety When Treating Potentially Violent Patients

Hayden Library - TL795.7.S33 2019

Rotch Library - HT169.I5 M36 2014

Rotch Library - DS485.C34 P38 2013

Rotch Library - TR647.S53 2017

Rotch Library - JV7590.M4864 2018

Rotch Library - DT295.C455 2016

Rotch Library - DT47.I43 2018

Rotch Library - GT510.F37 2015

Rotch Library - PJ7760.S89 Z59 2014

Each will have one vote and Patel will hold an additional tie-breaker, guided by a newly established inflation target

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.

Hayden Library - PN6727.S525 B67 2017